Lung Cancer
516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
- Details
ClinicalTrials.gov ID:
NCT03906071
Diagnosis Type:
NA
USOR Number:
- Address
1441 N Beckley Ave, Suite 102
Dallas, TX 75203
P: (214) 943-9911